A new drug, like a new movie star, is nurtured with care. It is "discovered" (often by a noncommercial scientist); it wins a contract with a drug manufacturer, who usually changes its name. It gets an advance buildup in medical and drug trade journals. At last, when ready to meet the public, it is launched on its career with a splash of publicity.
The new drug, Kutrol,* launched last week by Parke, Davis & Co. (the M-G-M of Pharmaceuticals) as a cure for peptic (stomach) ulcers, has passed through all these stages. It was developed by Dr. David J. Sandweiss of Harper...
To continue reading:
or
Log-In
